Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 5/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487188 | 1.00 | PDGFRA (0.59) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL22009936 | 0.94 | PDGFRA (0.56) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL20032552 | 0.92 | PDGFRA (0.51) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL31554535 | 0.92 | FLT3 (0.54) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487138 | 0.91 | KDR (0.50) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL22960033 | 0.91 | KDR (0.50) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL13936618 | 0.91 | PDGFRA (0.52) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL165288 | 0.91 | PDGFRA (0.52) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL30697769 | 0.91 | PDGFRA (0.52) | PDGFRAKDRFGFR2PDGFRBMET | |
| SCHEMBL12635542 | 0.91 | MET (0.53) | PDGFRAKDRFGFR2METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294804-B1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-113121429-B | C-Met kinase inhibitor and preparation method and application thereof | 鲁南制药集团股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-113195471-B | Polysubstituted pyridone derivative and application thereof in medicine | 苏州浦合医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-112236430-B | Cyclopyrazolone formamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-110283165-B | 4-phenoxy quinoline alpha-acyloxy amide compound and preparation method and application thereof | 威海惠安康生物科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1566379-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-24 | — | — | EP | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | PDGFRA 1935/4885KDR 2892/4885FGFR2 3433/4885 |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885KDR 4/4885FGFR2 90/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885KDR 5/4885FGFR2 78/4885 |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | PDGFRA 372/4885KDR 211/4885FGFR2 2/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | PDGFRA 1935/4885KDR 2892/4885FGFR2 3433/4885 |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | AXL, WEE1, FLT3 | PDGFRA 236/4885KDR 73/4885FGFR2 61/4885 |
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | PDGFRA 318/4885KDR 212/4885FGFR2 103/4885 |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | PDGFRA 1935/4885KDR 2892/4885FGFR2 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.